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Abstract  
Objective 
This study investigated differences in cardiorespiratory fitness, muscular function, perceived 
exertion and anxiety/depression between patients and healthy controls(HC) and assessed which of 
these variables may account for fatigue experienced by patients. 
Measurements 
Fatigue was measured in 48 AAV patients and 41 HC using the Multi-Dimensional Fatigue Inventory 
(MFI-20) focusing on the physical component. Quality of life, anxiety/depression and sleep quality 
were assessed by validated questionnaires. Muscle mass was measured by DEXA scan, strength as 
the maximal voluntary contraction (MVC) force and endurance as sustained isometric contraction at 
50% MVC of the quadriceps.  Voluntary activation was assessed by superimposed electrical 
stimulation.  Cardiorespiratory fitness (VO2max and O2pulse) and perceived exertion (Borg scale) 
were measured during progressive submaximal exercise.   
Results 
Patients reported elevated physical fatigue scores compared to HC (patients MFI-20 physical 13 (IQR 
8-16), HC MFI-20 physical 5.5 (IQR 4-8); p<0.001). Muscle mass was the same in both groups but 
MVC and time to failure in the endurance test were lower due to reduced voluntary activation in 
patients.  Estimated VO2max and O2pulse were the same in both groups. For the same relative work 
load, patients reported higher ratings of perceived exertion which correlated with reports of MFI-20 
physical fatigue (R2=0.2). Depression (R2=0.6), anxiety (R2=0.3) and sleep disturbance (R2=0.3) all 
correlated with MFI-20 physical fatigue. 
Conclusion 
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These observations suggest fatigue in patients is of a central rather than peripheral origin, supported 
by associations of fatigue with heightened perception of exertion, depression, anxiety and sleep 
disturbance, but normal muscle and cardiorespiratory function.   
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Significance and Innovations: 
Fatigue in patients with ANCA-associated vasculitis is due predominantly to a complex mix of 
psychosocial factors.  
This study is the first to suggest that physical fatigue is unrelated to muscle problems or 
cardiorespiratory fitness in patients with ANCA-associated vasculitis. 
Increased perception of effort and other factors such as sleep disturbance, anxiety and depression 
are important in fatigue and may be amenable to therapy. 
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Many patients with ANCA-associated vasculitis (AAV) complain of fatigue despite being in disease 
remission, and this is strongly associated with impaired quality of life(1-3).  There are currently no 
recommended treatments for fatigue in these patients, and a better understanding of the aetiology 
would be an important first step in developing an effective treatment.  Fatigue in patients with AAV 
is associated with a wide range of other complaints including, pain, sleep disturbance, dysfunctional 
coping strategies, inflammation(2) and reduced exercise capacity(4). These findings resemble those 
for other  chronic conditions such as rheumatoid arthritis(5), systemic lupus erythematosus(6), 
multiple sclerosis(7, 8) and fibromyalgia (9-11) where fatigue is acknowledged to be of complex 
aetiology.  
 
Our previous work has shown a reduced exercise capacity in patients with AAV(4), with patients 
reporting fatigue as the limiting factor. When considering the mechanisms by which fatigue may 
arise, it is useful to divide them into ‘peripheral’ and ‘central’ mechanisms. Peripheral mechanisms 
of fatigue are those which result from physiological problems within either the neuromuscular or 
cardiorespiratory systems which make physical effort more demanding.  Treatment of AAV often 
necessitates the prolonged use of glucocorticoids, which are known to lead to muscle wasting(12, 
13) and might therefore be expected to cause peripheral fatigue, although whether patients with 
AAV in remission have evidence of muscle wasting is unknown. Another cause of peripheral fatigue 
is cardiorespiratory deconditioning(14), which results in normal everyday tasks being carried out at a 
higher percentage of maximum heart rate. It is not known whether patients with AAV in remission 
are significantly deconditioned. Peripheral fatigue may be measured relatively easily by making 
objective measurements, for example by measuring muscle strength during isometric contractions in 
a sport science laboratory. Central fatigue describes functional abnormalities of the CNS such as 
increased perception of exertion, reduced motivation or reduced central motor activation, which are 
probably caused by alterations in neurotransmitter pathways within the brain.(15) Such alterations 
in pathways within the brain cannot be easily measured, but surrogates such as central motor 
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activation may be measured using recognised sport science techniques including the superimposed 
electrical stimulation of muscles during voluntary isometric contraction.  
 
We have undertaken a systematic evaluation of the possible relationship between various measures 
of cardiorespiratory and neuromuscular fitness and the severity of self-reported fatigue in a 
representative sample of AAV patients in disease remission compared with healthy control subjects.   
In addition we have investigated the participants’ perception of effort during exercise testing and 
their ability to voluntarily contract and maintain contraction in their quadriceps muscles as a 
measure of central factors associated with fatigue. 
 
Subjects and Methods 
Subjects: Patients meeting the European Medicines Agency (EMA) vasculitis classification 
algorithm(16) for AAV were recruited consecutively from the University Hospitals Birmingham NHS 
Foundation Trust vasculitis clinic. All patients were in sustained remission (Birmingham Vasculitis 
Activity Score =0 for >6 months, with stable dose of prednisolone ≤10mg) at the time of the study. 
Patients with acute illness, significant cardiorespiratory disease, end-stage kidney disease (ESKD), 
pregnancy or co-morbidities that prevented exercise were excluded from the study.  The healthy 
controls were recruited from friends or relatives of patients, from the wider community through 
outreach research clinics, or from the hospital. Individuals were included if they were not known to 
suffer from AAV, chronic kidney disease or from any other major organ disease on questioning. 
Minor illnesses such as osteoporosis, hypertension or hyperlipidaemia were permissible, provided 
that there was no known damage to any major organ, and that the illness had not been previously 
associated with fatigue in the literature.  All participants in both groups were screened for eligibility 
and recruited by one of the authors (AM). Investigations were carried out during an extra visit to the 
hospital, and although free parking was offered no other compensation was paid to participants. 
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91 patients with AAV were screened for entry to the study. Of those, 25 were not suitable due to 
exclusion criteria (7 ESKD, 10 poor mobility, 2 ischaemic heart disease, 2 tracheal stenosis, 4 
miscellaneous acute illness) and 18 declined. 75 healthy controls were screened for inclusion; none 
were ineligible, but 34 declined. Forty eight patients and 41 healthy controls were recruited to the 
study. 
 The Birmingham, East, North and Solihull Research Ethics Committee approved the study (REC ref 
number 09/H1206/113), and written informed consent was obtained from all patients according to 
the Declaration of Helsinki. 
 
Data Collection: Participants’ demographic data, disease duration and characteristics, and duration 
of prednisolone use and current prednisolone dose were recorded, together with an assessment of 
disease damage using the vasculitis damage index (VDI; (17)).  
 
Fatigue, Quality of Life, Anxiety, Depression and Sleep: Fatigue was quantified using the Multi-
Dimensional Fatigue Inventory (MFI-20)(18), which characterises fatigue into five dimensions 
(General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Activity and Reduced Motivation), with 
scores ranging from four (no fatigue) to twenty (maximal fatigue) for each dimension. We used 
physical fatigue score throughout this study. The SF-36 was used to assess health-related quality of 
life (HRQOL) and pain (19); this questionnaire comprises eight sections (Physical Functioning, Role-
Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental 
Health), and raw scores are transformed into a 1-100 scale for each domain, with high scores in each 
subscale indicating good HRQOL. The Hospital Anxiety and Depression Scale (HADS) was used to 
generate summary scores for clinically relevant anxiety and depression symptoms, with possible 
scores ranging from 0-21 for each symptom (20). Sleep quality was assessed with The Pittsburgh 
Sleep Quality Index (PSQI)(21); seven component scores are summed to yield a Global PSQI Score 
which ranges from 0 (best possible sleep quality) to 21 (worst possible sleep quality).  
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Body composition: Body Composition was measured by dual energy x-ray absorptiometry (DEXA; 
Hologic Discovery A QDR Bone Densitometer, Massachusetts, USA)(22). 
 
Muscle Strength and Voluntary Activation: Quadriceps muscle function was assessed with the 
subject sitting with the knee flexed at 90o and force measured at the ankle(23).  Three to five brief (3 
secs) isometric maximal voluntary contractions (MVCs) were performed at one-minute intervals with 
electrical stimulation immediately before and at the peak of force. Participants could see the force 
record and received strong verbal encouragement to achieve maximal effort. The extent of voluntary 
activation was assessed with the twitch interpolation technique(24). An electrical stimulation to the 
muscle provides an estimate of the force of the muscle contraction if the muscle is fully activated. If 
a muscle is being voluntarily activated to its fullest possible extent by a participant, then a 
superimposed electric stimulus will achieve no increase in the force generated by that contraction; 
the extent of voluntary activation (VMA) can therefore be estimated by the equation ‘VMA = [1- 
(force generated by super-imposed electrical stimulation/force generated by resting electrical 
stimulation) x100]’. Peak voluntary force and the degree of voluntary activation were recorded, and 
these variables were further used to calculate the ‘true maximum contraction (TMC) force’, i.e. the 
force which that muscle could exert if it were fully activated. 
 
Muscle Endurance: Participants were asked to maintain a quadriceps contraction at 50% of their 
peak voluntary force for as long as possible.  Participants matched the force trace to a target on the 
computer screen and received verbal encouragement to continue.  The end point was either 
volitional fatigue or when the force fell more than 5% below the target for 5 seconds.  The muscles 
were electrically stimulated before and every 10s during the contraction to monitor the level of 
voluntary activation using the same principles as previously described. As the motor units of a 
skeletal muscle exhaust energy stores during a sustained contraction, the brain will normally 
compensate by recruiting increasing numbers of motor units in order to maintain a constant overall 
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force.A superimposed electrical stimulus would normally generate no additional force at the point of 
volitional fatigue therefore any additional force generated by the superimposed electrical stimulus is 
interpreted as evidence of reduced central volitional activation of the muscle. 
 
Cardiorespiratory Fitness: Participants underwent a 10 minute incremental exercise protocol on a 
cycle ergometer (Lode, Groningen, the Netherlands), beginning with a 1 minute warm-up at a 
workload of 10W, followed by 3 periods of three minutes each at 25W, 50W and 75W. Oxygen 
uptake (VO2) was recorded continuously with an on-line gas analysis system (MOXUS, AEI 
Technologies, USA). Maximum oxygen uptake (VO2max) was estimated by extrapolating the linear 
relationship between O2 uptake and heart rate(25)  to the estimated age-related heart rate(26) and 
expressed as ml/min/kg.  Oxygen Pulse (O2Pulse) was determined as the slope of the linear 
regression of VO2 against heart rate(27).   
 
Perception of Exertion: During the exercise participants were asked to rate their perception of 
exertion (RPE) using the Borg 6-20 scale (Borg, 1982) every three minutes, just before the transition 
to the next work load.  
 
Statistical Analysis 
All analyses were carried out using IBM SPSS Statistics 21.0. Categorical data was summarised with 
percentages, and quantitative data was summarised with median and interquartile range (IQR). 
Comparisons of results between the groups were assessed using Fisher’s exact tests for categorical 
data and Mann-Whitney tests for quantitative data, and Spearman’s rank order correlation was used 
to assess the strength of associations between variables.  
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Results 
Participant Characteristics and extent of fatigue:  Forty eight AAV patients and 41 healthy controls 
participated in the study. Except for expected clinical features, there were no significant differences 
between AAV patients and healthy controls (Table 1). AAV patients reported higher levels of physical 
fatigue compared with healthy controls (Table 1).  All fatigue domains of MFI-20 were elevated in 
AAV patients compared with healthy controls (supplementary figure 1).  
 
There were no significant associations in the AAV patients between MFI-20 physical fatigue and 
phenotypic disease category, lung or renal involvement, eGFR or Hb, but there was a significant 
association between MFI-20 physical fatigue and VDI (rs=0.418, p=0.034).  
 
Body composition: Patients had significantly higher BMI and greater body fat than the controls 
(Table 2). No evidence was found of muscle wasting in the patients, as lean body mass and lean leg 
mass were the same as controls.  An identical pattern was seen when the data was analysed by sex. 
 
Muscle function: Patients had reduced quadriceps MVC compared to controls (Table 2). This was 
due to the tendency to reduced voluntary muscle activation in patients compared with controls 
(Table 2). When the MVC force was corrected for voluntary muscle activation to give the TMC force 
there was no difference between the two groups. TMC was closely related to the lean leg mass. The 
ranges of both lean leg mass and strength were the same in the two groups and their muscles 
functioned equally well in generating force (Fig 1). There was no association of fatigue with vountary 
activation (rs=-0.142, p=0.169), MVC (rs=-0.208, p=0.352) or TMC (rs=-0.144, p=0.344) in patients 
with AAV. 
 
During the muscle endurance test, patients sustained a contraction at 50% of their maximum 
voluntary contraction force for a significantly shorter time than the controls (Table 2).  Muscle 
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activation at the start of the endurance test was not different between the two groups, but at the 
time of fatigue, voluntary activation was less in the patient group, and thus central fatigue greater 
(Table 2).   
 
When analysing all study participants together, a  strong correlation was seen between MFI-20 
physical fatigue  and endurance time (rs=-0.310, p=0.004). However, when the AAV patients were 
analysed alone these correlations were lost (MFI-20 physical fatigue  and endurance time rs=-0.014, 
p=0.0.925). 
 
Cardiorespiratory testing:  There were no adverse events during the cycle ergometer exercise.  Eight 
females and one male patient stopped the exercise before the final stage, complaining of a 
combination of dyspnoea and leg pain. Data from four AAV patients were excluded from the analysis 
due to technical problems.   
 
VO2max expressed relative to total body mass was lower in the patient group, almost achieving 
statistical significance (Table 2), but this was largely due to the greater adiposity of the patients, and 
when VO2max was expressed relative to lean body mass there was no difference between the 
groups (Table 2). VO2max is most often expressed relative to total body mass because it is more 
difficult to measure lean body mass, but since adipose tissue is not metabolically active during 
exercise it is physiologically more correct to express oxygen consumption relative to lean body mass. 
O2Pulse is another measure of cardiorespiratory fitness which has the advantage that it does not rely 
on estimated values for maximum heart rate and weight. There were no differences in O2Pulse 
between patients and controls (p=0.184; Table 2). There was no association between 
cardiorespiratory fitness using O2 pulse and MFI-20 physical fatigue (rs=0.110, p=0.341) 
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Subjects were asked to rate their perception of exertion using the Borg scale. Although patients and 
control subjects finished the exercise at very similar relative work rates, as judged by their heart 
rates as a percentage of their age predicted maximum, their reported perception of exertion was 
significantly greater (Fig 3A). To assess whether physical fatigue was related to this increased 
perception, the Borg score at the end of exercise was expressed as a fraction of the score expected 
for that heart rate (RPEindex), assuming that a score of 20 would be obtained at maximum heart 
rate.  In the patient group there was a correlation between perception of effort and self-reported 
physical fatigue on the MFI-20 (Fig 3B). Interestingly, RPEindex also associated with reduced activity 
(rs=0.319, p=0.003) and reduced motivation (rs=-0.451, p<0.001) domains of the SF36 questionnaire. 
 
As previously reported (2), all indices of quality of life, depression, anxiety, pain and sleep 
disturbance were significantly worse for the patient group than the controls (Table 3). MFI-20 
physical fatigue associated with all indices of quality of life as we have previously published (2) (data 
not shown). Within the patient group there was a strong correlation between MFI-20 physical 
fatigue and anxiety, depression, pain and sleep quality. In addition, RPEindex correlated with anxiety, 
depression, and sleep quality, although less strongly; the correlation between RPEindex and pain was 
not significant. (Table 4). 
 
Discussion 
The present study extends previous observations (2, 3) that fatigue is a major factor determining the 
quality of life in patients with AAV who are in stable remission. This is the first study that has 
systematically examined the role of the cardiopulmonary and neuromuscular systems as causes of 
fatigue in patients with AAV. In this study the patients showed no evidence of deficits in muscle 
mass or function or of cardiopulmonary fitness. They did however, have an enhanced perception of 
exertion and reduced ability to sustain a voluntary muscle contraction. 
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The extent and nature of fatigue experienced by the patients and controls is comparable with that 
reported in our previous studies and in other diseases where fatigue is common, such as Primary 
Biliary Cirrhosis and Chronic Fatigue Syndrome(28). Interestingly, this study shows an association 
between disease damage and fatigue, which differs from our previous study, and may reflect higher 
levels of disease damage than in the previous study(2). 
  
During the sustained muscle contraction the patients reached the point of volitional fatigue sooner 
than the control subjects. The superimposed electrical stimulation showed that the two groups were 
activating their muscles to a similar extent at the start of the contraction but at the point of muscle 
fatigue patients were voluntarily activating their muscles to a lesser extent than the healthy control 
subjects. If the loss of force during the sustained contraction was entirely due to peripheral muscle 
fatigue, it would be expected that superimposed electrical stimulation would not further increase 
contraction at this point.  In fact, additional electrical stimulation showed that voluntary activation 
at this point was only 68% for the patients and 75% for the control subjects, indicating both groups 
experienced considerable central fatigue, but that the contribution of central fatigue was 
significantly greater for the patients.  The data showed no differences in lean body mass or lean leg 
mass between the patients and control subjects, suggesting the corticosteroid treatment had not led 
to muscle wasting. Across both groups there was a significant association with physical fatigue and 
endurance time. However this was lost when analysing patients alone suggesting that either the 
study was underpowered to find such correlations, or that the apparent correlations were simply a 
reflection of the differences between the two groups. 
The perception of effort during the submaximal exercise test, expressed as RPEindex, was 
significantly greater for patients than controls at the same workload. It has previously been 
suggested that fatigue maybe due to reduced cardiorespiratory fitness, but in our study VO2max was 
not significantly lower in the patient group when corrected for body composition, indicating that the 
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patient group was no less aerobically fit than the controls.  We estimated maximum oxygen uptake 
by extrapolating to maximum heart rate, calculated from age. It is generally acknowledged that 
estimating maximum heart rate from age lacks precision and consequently we also report the 
Oxygen Pulse as a measure of cardiorespiratory function which does not depend on maximum heart 
rate or body mass. Oxygen Pulse largely reflects stroke volume during exercise(27)  and did not differ 
between the patient and control groups, neither did it correlate with any aspect of fatigue. 
 
This study suggests that the feeling of fatigue experienced by patients with AAV cannot be explained 
by any deficit in muscle mass or function, or by a lack of cardiopulmonary fitness.  Our previous 
observation of reduced exercise capacity in patients with ANCA-associated vasculitis(4) may be 
explained by increased perception of exertion, as demonstrated in the present study, which led to 
early volitional fatigue.  
 
Scores for depression, anxiety, pain and sleep disturbance were all raised in the patient group 
compared with controls, as has been reported previously (2, 29); all of these measures showed 
significant correlations with physical fatigue, and all except pain correlated significantly with 
RPEindex. Our findings of increased perception of effort and reduced voluntary activation of muscles 
suggest increased central fatigue in patients with AAV, perhaps, in part, due to depression, anxiety, 
and poor sleep quality. RPEindex associated with reduced activity and motivation supporting this 
suggestion. Similar findings are reported in other diseases associated with increased fatigue, 
including fibromyalgia and multiple sclerosis (MS) where there is also evidence of central fatigue (7, 
8, 10). Patients with fibromyalgia reach the point of volitional muscle contraction failure more 
rapidly than healthy controls. Fibromyalgia is associated with hypersensitisation to many stimuli (30) 
and it has been suggested that these patients may fail to activate endogenous pain inhibitory 
mechanisms during muscle contraction (31) resulting in central fatigue. Interestingly, patients with 
AAV exhibit increased pain scores that correlated with fatigue (2), although not with perception of 
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effort. AAV patients have increased rates of fibromyalgia compared with the general population(29). 
None of our patients stopped the investigations due to pain in their joints or muscles. 
 
Several limitations of this study require acknowledgement. It is impossible to measure central 
factors directly, and we have therefore used perception of effort and voluntary muscle activation as 
surrogate markers. Increased perception of effort and reduced voluntary muscle activation are likely 
to make physical effort more demanding thus constituting a barrier to physical activity(3, 32). 
Habitual exercise was only assessed in this study by questionnaire data, and could have been 
confirmed by the use of accelerometers for a period of time in some or all of the participants. The 
use of super-imposed electrical stimulus during voluntary isometric muscle contraction (the ‘twitch 
interpolation technique’) is a widely used method for assessing voluntary muscle activation, but 
could possibly have influenced some participants to cease muscle contraction earlier than they 
would otherwise have done, particularly during the endurance test. The optimum measurement to 
assess cardio-respiratory fitness is true VO2max, but the measurement of this involves extreme 
physical stress and is not safe to measure in this population; the measurements of aerobic fitness 
made in this study were a necessary compromise. Although of cross-sectional design and relatively 
small size, the present study is the largest to investigate the complex physiological and central 
factors associated with fatigue in AAV. This study adds to our understanding of the complexity of 
fatigue in patients with AAV and is similar to findings in other chronic diseases where fatigue is 
common. However further studies confirming our results are required. 
 
This raises the question as to how these results should inform the treatment of fatigue in AAV. It is 
clear that using exercise simply to increase aerobic capacity or muscle strength is unlikely to be 
effective, since neither differed from healthy controls or contributed to fatigue in this study. It is 
possible, however, that structured physical activity, along with addressing the individual 
psychological components, may be beneficial.  There is recent evidence showing that both exercise 
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and cognitive behavioural therapy can help patients with chronic fatigue syndrome(33, 34) and some 
combination of the two might also be useful in AAV patients.   Establishing an integrated care 
pathway which acknowledges fatigue to be a real and important problem and addresses specific 
problems such as depression, anxiety and sleep disturbance would be likely to help patients. An 
example of such a pathway has been reported to provide significant improvements in symptoms of 
fatigue for patients suffering from primary biliary cirrhosis(35). 
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Table 1 Characteristics of the study participants. 
 AAV Healthy p value 
N 48 41 - 
Age (yrs) 58 (47-65) 58 (49-63) 0.6 
Male 26 (54%) 23 (56%) 1.0 
White ethnicity 48 (100%) 40 (98%) 0.5 
Hb (g/l) 135 (124-146) 140 (131-148) 0.2 
MDRD eGFR 
(ml/min/1.73m2) 
66 (50-78) 82 (74-90) 
<0.001 
Disease duration 
(months) 
64 (22-98) N/A 
- 
VDI 4 (2-5) N/A - 
Median current 
prednisolone dose 
(mg/d) 
 
5 (0-5) N/A - 
Median duration  of 
prednisolone use 
(months) 
 
64 (22-98) N/A - 
GPA 
 
29 (60.4%) N/A - 
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MPA 
 
16 (33.3%) N/A - 
Renal Involvement 
 
26 (54.2%) N/A - 
Lung Involvement 
 
17 (35.4%) N/A - 
> 1 Hr of Sport / Wk 
 
28 (70.0%) 30 (83.3%) 0.172 
MFI-20 Physical 
Fatigue 
13 (8-16) 5.5 (4-8) <0.001 
 
Gender, ethnicity and ‘> 1 Hr of Sport /Wk’ are expressed as number of participants (column 
percentage of valid data); all other results are expressed as median (Interquartile Range). 
Abbreviations; Vasculitis Damage Index, VDI; Estimated Glomerular Filtration Rate calculated using 
Modification of Diet in Renal Disease formula (MDRD eGFR); not applicable N/A. 
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Table 2. Body composition and functional measures of muscle function and cardiorespiratory fitness 
in patients and controls 
 
measure AAV Healthy significance 
Body 
Composition Lean body mass (kg) 52.4 (42.2-61.9) 51.4 (45.0-59.8) p=0.979 
 
fat mass (kg) 25.1 (18.5-35.4) 19.5 (14.5-24.4) p=0.004 
 
Body mass index 
(kg/m2) 28.1 (24.8-32.0) 24.8 (23.6-27.9) p=0.019 
 
lean leg mass (Kg) 8.3 (6.7-9.9) 8.8 (7.1-9.8) p=0.483 
isometric  MVC (N) 275 (211-337) 322 (240-385) p=0.050 
strength activation % 68 (58-81) 76 (67-86) p=0.074 
 
TMC (N) 347 (277-441) 395 (315-480) p=0.315 
muscle initial activation (%) 46 (32-53) 42 (32-52) p=0.487 
endurance endurance (sec) 70 (50-90) 91 (71-122) p=0.006 
 
fatigue activation (%) 68 (58-79) 75 (68-83) p=0.038 
CV fitness VO2 max (ml/kgBM) 25.1 (21.8-31.8) 30.3 (24.7-35.2) p=0.056 
 
VO2 max (ml/kg lean 
BM) 37.9 (34.1-49.5) 43.4 (38.2-50.5) p=0.103 
 
O2 pulse (ml/beat) 17.3 (12.2-24.5) 20.9 (14.3-25.0) p=0.184 
 
 
Isometric strength: MVC, maximum voluntary contraction; TMC, True maximum contraction force 
after correcting MVC for % activation. Muscle endurance: time to hold 50% MVC; Initial Activation, 
voluntary muscle activation at the start of the contraction, Fatigue activation, voluntary muscle 
activation at the point of fatigue. CV Fitness: VO2max, estimated maximum oxygen uptake, 
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normalised for either total body mass (BM) or lean body mass (LBM). Data given as median 
(interquartile range). 
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Table 3 Quality of life, anxiety/depression and sleep disturbance are all worse in AAV patients 
compared with Healthy controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scores for health-related quality of life from the SF-36 questionnaire, depression and anxiety from 
the HADS questionnaire; sleep disturbance (PSQI) from the Pittsburgh Sleep Quality Index.  Data are 
given as median (Interquartile range) 
 
Abbreviations AAV, ANCA associated vasculitis; PSQI , Pittsburgh Sleep Questionnaire Index; HADS, 
Hospital Anxiety and Depression Score 
  
 AAV Patients Healthy Controls P 
Physical functioning 75 (48-93) 100 (90-100) <0.001 
Physical Role Impairment 25 (0-100) 100 (100-100) <0.001 
Bodily Pain 62 (52-84) 84 (74-100) <0.001 
General Health 50 (25-67) 87 (72-97) <0.001 
Vitality 50 (30-60) 80 (70-85) <0.001 
Social Functioning 88 (56-100) 100 (100-100) <0.001 
Emotional Role Impairment 100 (33-100) 100 (100-100) <0.001 
Mental Health 68 (52-80) 84 (76-88) 0.001 
Physical Component Score SF36 42.5 (32.4-50.3) 55.3 (53.0-57.5) <0.001 
Metal Component Score SF36 48.4 (39.2-55.0) 56.3 (54.4-58.4) <0.001 
Anxiety (HADS) 7 (3-9) 3 (1-6) 0.005 
Depression (HADS) 5 (2-8) 1 (0-2) <0.001 
Global Sleep Disturbance 7 (4-10) 4 (2-5) <0.001 
Fatigue and AAV 
 
28 
 
Table 4. Physical fatigue and RPEindex as a function of psychological variables in patients with ANCA-
associated vasculitis.   
 
 Correlation with physical 
fatigue (rs)
 
Correlation with RPEindex (rs) 
Anxiety score 0.32; p<0.001 0.09; p=0.041 
Depression score 0.57; p<0.001 0.09; p=0.049 
Global PSQI score 0.32; p<0.001 0.11; p=0.026 
Pain 0.27; (p<0.001) 0.07; p=0.066 
 
Abbreviation: Global PSQI, Global Sleep Quality Score from the Pittsburgh Sleep Quality Index.  Data 
are from the Patient group only. 
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Figure Legends 
Figure 1. There was no difference in the relationship between lean leg mass and muscle strength 
when comparing patients and healthy controls (TMC is MVC corrected for activation).  Closed 
symbols and dashed regression line patients, open symbols and solid regression line control 
subjects. The formula for the Patient group regression line top left, and for the Controls bottom 
right. p=0.777 for comparison of the slopes, and p=0.681 for comparison of intercepts.  
 
Figure 2 
 Figure 2A. Perceived exertion as a function of work rate is significantly greater in patients than 
controls (p=0.006).  The Borg scale ratings (RPE) at the end of exercise are shown compared to 
exercise intensity, expressed as actual heart rate as a percentage of estimated age-related heart 
rate. Close symbol, patients; open symbol, control.  Data given as median and IQR. Figure 2B. 
Physical fatigue compared to perceived exertion expressed as RPEindex, which takes into account the 
relative workload at which the subjects were working.  Data are for the patient group only.  
 
Supplementary  
Figure 1: Self-reported fatigue using the Multi Factorial Index (MFI-20) domains. Bars indicate 
median, boxes indicate the interquartile range and whiskers indicate the range. 
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